Bioreactors Market Size By Product (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Usage (Developmental, Pre-clinical & Clin

Bioreactors Market Size By Product (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Usage (Developmental, Pre-clinical & Clinical, Commercial Production), By End-use (R&D Organizations, Biopharma Manufacturers, Contract Manufacturing Organizations (CMOs)), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 - 2032

Global bioreactors market is set to witness substantial growth between 2023 and 2032 primarily owing to the technological advancements in bioreactors. Increasing adoption of single-use bioreactors owing to their additional benefits like efficiency in air and gas transfer, proper mixing of cells, and flexible operating conditions for better results will fuel the product demand in near future.

Overall, the bioreactors market has been bifurcated in terms of product, molecule, end-user, cell, usage, and region.

Based on product, the bioreactors market is likely to be characterized by the single-use segment. This segment is likely to grow at 15.5% CAGR through the estimated timeframe owing to the increasing adoption of single-use bioreactors for research purposes and to produce vaccines for a range of infections including COVID-19. Besides, it comes with a range of benefits for the researchers as well which is likely propel its demand in the upcoming times.

On the basis of molecule, the stem cells segment is likely to grow at more than 12.5% CAGR over 2023-2032. There is a widespread adoption of stem cell therapy due to an increase in the number of cancer cases. Furthermore, supportive government initiatives, increasing R&D expenditure, and rising demand for cell-based products are likely to fuel the segmental expansion of stem cell-based products in the future.

In the context of end-user, the biopharma manufacturers segment is poised to witness substantial growth. This can be credited to the rising adoption of advanced technologies which can be used to ease complex manufacturing.

Within the category of cells, the bioreactors market will be driven by the bacterial cells segment. Bacterial cells are used to produce several pharmaceutical therapeutics. Increasing usage of them by research institutes and manufacturers will positively drive the market growth through the analysis timespan.

Based on usage, the bioreactor market is likely to be driven by the commercial production segment. This segment will witness substantial growth due to the increasing burden of chronic diseases, introduction of new companies, and mass production of vaccines. Moreover, reusable bioreactors are cost-effective and convenient which will also enhance the segmental revenue through the stipulated timeframe.

In the regional landscape, the bioreactors market in the MEA region will grow at a robust rate through the estimated timeframe. Increasing cases of infectious diseases in African countries along with the rising demand for drugs to cure them will likely bolster the market scenario in the upcoming time.

Some of the key players in the bioreactors market include Danaher Corporation, Thermo Fisher Scientific, Getinge (Applikon Biotechnology), CESCO Bioengineering Co. Ltd, Bbi Biotech, Shanghai Bailun Biotechnology co., Ltd., PBS Biotech, Pierre Guerin SAS (Engie), and Solaris Biotech Solutions.